CaPP3 is go!
posted on Thursday, 1st September 2011
Now that we have the result of the CAPP2 study which
shows that regular aspirin significantly reduces cancer risk in
Lynch syndrome, we now need to try and work out the best
If you carry a mismatch repair gene defect and would like to
help in our worldwide effort to answer this important question
please leave us your email address and we will contact you.
Our plan is to invite volunteers to be randomly put into one
of three groups taking either 600mg (2 tablets like in CAPP2),
300mg (one tablet) or a mini aspirin (75-100mg) then see what
happens over the next few years. we need at least 3000 people
to make this work. If we can, it will give the next
generation the best chance of avoiding cancer while keeping side
effects to a minimum.
To show your interest in participating in the trial
please register your details.